the lovenox back-flip costly, page-18

This is the excerpt from the report.... the way its written is that the lovenox decision was made even before the building of the new headquarters.....

We believe the time and resources that have gone into creating the Unilife that exists today are inadequately reflected in its market capitalization. Indeed, the Company has risen to the challenges that followed a strategic decision by Sanofi to abandon Lovenox® to competitors rather than attempt to protect it with the patented Unifill safety syringe. Since then, a new headquarters/manufacturing facility has opened with multiple-tiers of clean rooms to meet the rigorous requirements of global regulatory agencies. An expansion of the product development team has yielded four additional platform technologies that enable the Company to satisfy the vast majority of drug delivery needs of the pharmaceutical industry. That group is now complemented by engineers and scientists whose tasks include customizing the platform technologies for specific drugs and clinical applications. Manufacturing is performed with semi-automated systems for low-volume products, such as the RITATM auto-injector, and via fully automated machinery for high-volume products, including the Unifill syringe. The patent estate has expanded from 32 patents in 16 countries at the end of fiscal 2010 (years end June 30th) to 60 patents in more than 20 jurisdictions worldwide at the close of fiscal 2012. In addition, a team of experienced business development executives have accelerated marketing of the Unilife product portfolio to the drug industry.